title: Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.
abstract: To understand the relationship between pituitary adenoma and carcinoma, four adrenocorticotropic hormone-producing pituitary adenomas and corresponding metastatic carcinomas were studied. All were functional macroadenomas (three cases of Nelson syndrome and one of Cushing disease) that initially invaded the sella turcica and occurred in women ranging in age from 17 to 66 years (mean 45 years). Metastases (two craniospinal and two systemic) occurred after latency periods of 6 to 13 years. Histological specimens were immunostained for pituitary hormones, Ki-67 antigen (MIB-1), p53 and p27 proteins, D-type cyclins, and glucocorticoid receptor messenger (m)RNA. The DNA content of the specimens was assessed using Feulgen stain. Reactivities were quantified by digital image analysis. Primary/recurrent lesions and metastatic tumors differed according to their respective mean mitotic indices (1.2/10 hpf compared with 4.3/10 hpf), MIB-1 labeling (1.7% compared with 8%), p53 staining (37.3% compared with 49.9%), and p27 labeling (48% compared with 25%). Cyclin D, immunoreactivity provided no prognostically significant information. Glucocorticoid receptor mRNA was detected in all cases. Results of a ploidy analysis were variable and nonprognostic. In keeping with the 2000 World Health Organization classification of endocrine neoplasms, our findings support the concept that primary tumors that exhibit mitotic activity, an increased (> 3%) MIB-1 labeling index, and/or p53 immunoreactivity should be termed "atypical adenomas" to denote their aggressive potential and the possibility of future malignant transformation.
authors.affiliation: Mayo Clinic, Rochester, Minnesota 55902, USA.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Gaffey
authors.forename: Bernd W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: Ricardo V
authors.initials: RV
authors.lastname: Lloyd
authors.forename: Peter C
authors.initials: PC
authors.lastname: Burger
authors.forename: Peter
authors.initials: P
authors.lastname: Robbins
authors.forename: Forouzandeh
authors.initials: F
authors.lastname: Fereidooni
authors.forename: Eva
authors.initials: E
authors.lastname: Horvath
authors.forename: Kalman
authors.initials: K
authors.lastname: Kovacs
authors.forename: Takao
authors.initials: T
authors.lastname: Kuroki
authors.forename: William F
authors.initials: WF
authors.lastname: Young
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Sebo
authors.forename: Darren L
authors.initials: DL
authors.lastname: Riehle
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Belzberg
mesh_terms: D000236:Adenoma / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000328:Adult; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*
chemical_list: D000324:Adrenocorticotropic Hormone